One PDX, namely BT74, was used to accurately recapitulate glioma heterogeneity and the physiological expression of two GBM antigens, namely EGFRv3 and IL13Rα2, in pre-clinical studies of CAR T-cell approaches [111]. The gene discussed is IL13RA2; the disease is central nervous system cancer.